Doctor Vincenzo Quagliariello
National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology
Event: Heart Failure 2024
Topic: Cardio-Oncology
Session: Cardiovascular disease in special populations - cardio-oncology (1)
Combinatorial immune checkpoint blockade increases myocardial secretion of H-FABP, NT-Pro-BNP, NLRP-3, IL-1 and IL6: clinical implications in cardio-immuno-oncology
Event: Heart Failure 2024
Topic: Cardio-Oncology
Session: Young Investigator Award (YIA) Basic Science
Ipilimumab, pembrolizumab and nivolumab exerts different cardiac and vascular toxicity through DAMPs fibronectin-EDA, S100/calgranulin, galectine-3 and associated NLRP3 inflammasome-chemokine pathway
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Dapagliflozin enhanced the anticancer effects of the CTLA-4 blocking agent ipilimumab reducing its cardiotoxicity through galectine-3, Trimethylamine N-oxide (TMAO) and NLRP-3
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Fructosilation products and low doses of advanced glycation end-products promotes premature cell death of cardiac cells exposed to doxorubicin via activation of NLRP3, MyD88 and p53 downregulation
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Dapagliflozin associated to sacubitril/valsartan exerts additive cardioprotection during exposure to doxorubicin and trastuzumab through improvement of mytogenesis and reduction of MyD88/NLRP3
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Palmitoylethanolamide (PEA) reduces inflammation in cardiomyocytes and endothelial cells exposed to doxorubicin and trastuzumab through PPAR-a and NLRP3
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Sacubitril/valsartan improves ejection fraction and longitudinal strain in mice exposed to doxorubicin through the reduction of trimethylamine N-oxide, NLRP3 inflammasome and Galectine-3
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Co-incubation of evolocumab with trastuzumab emtansine (T-DM1) reduces cardiotoxicity through the reduction of MyD88-NLRP3 and galectine-3
Event: Heart Failure 2022
Topic: Cardio-Oncology
Session: Heart Failure ePosters - focus on Comorbidities and special population
Sacubitril-valsartan improves radial and longitudinal strain and ejection fraction in C57Bl/6 mice treated with doxorubicin through NLRP3 mediated pathways and reduction of cytokine storm
Event: EuroEcho 2021
Topic: Echocardiography, Other
Session: Young Investigator Award - Basic Science
